Zobrazeno 1 - 10
of 57
pro vyhledávání: '"recombinant human hyaluronidase PH20"'
Publikováno v:
Drug Delivery, Vol 30, Iss 1 (2023)
AbstractSubcutaneous (SC) infusion of large volumes at rapid flow rates has historically been limited by the glycosaminoglycan hyaluronan (HA), which forms a barrier to bulk fluid flow in the SC space. Recombinant human hyaluronidase PH20 (rHuPH20) d
Externí odkaz:
https://doaj.org/article/49d3a4a1a47840febc5260a5eca0a60b
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Drug Delivery, Vol 26, Iss 1, Pp 98-106 (2019)
ENHANZE® drug delivery technology is based on the proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20; Halozyme Therapeutics, Inc.) that facilitates the subcutaneous (SC) delivery of co‐administered therapeutics. rHuPH20 works by degr
Externí odkaz:
https://doaj.org/article/db94eb4355944ba4a608ab317f5696f8
Autor:
Marie A. Printz, BA, Samuel S. Dychter, MD, Emanuel P. DeNoia, MD, Rena Harrigan, MPH, Barry J. Sugarman, PhD, Monica Zepeda, PhD, Jennifer Souratha, BSc, David W. Kang, BSc, Daniel C. Maneval, PhD
Publikováno v:
Current Therapeutic Research, Vol 93, Iss , Pp 100604- (2020)
ABSTRACT: Background: Recombinant human hyaluronidase PH20 (rHuPH20) is used in subcutaneous formulations (eg, RITUXAN HYCELA [rituximab and hyaluronidase human], HERCEPTIN HYLECTA [trastuzumab and hyaluronidase-oysk], PHESGO [pertuzumab/trastuzumab/
Externí odkaz:
https://doaj.org/article/9727f714ed4549758640d27883f0f639
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Marina Meroni, Lavinia Morosi, Ilaria Fuso Nerini, Roberta Frapolli, Barbara Blouw, Lucia Minoli, Enrico Davoli, Paolo Ubezio, Luca Porcu, M. D'Incalci, Massimo Zucchetti, Nicolò Panini, Marika Colombo, David W. Kang
Publikováno v:
Journal of Experimental & Clinical Cancer Research : CR
Journal of Experimental & Clinical Cancer Research, Vol 40, Iss 1, Pp 1-13 (2021)
Journal of Experimental & Clinical Cancer Research, Vol 40, Iss 1, Pp 1-13 (2021)
Background Scarce drug penetration in solid tumours is one of the possible causes of the limited efficacy of chemotherapy and is related to the altered tumour microenvironment. The abnormal tumour extracellular matrix (ECM) together with abnormal blo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c192e2b977107ce328cd64d0d5191a5
http://europepmc.org/articles/PMC8434701
http://europepmc.org/articles/PMC8434701
Publikováno v:
Drug Delivery, Vol 26, Iss 1, Pp 98-106 (2019)
ENHANZE® drug delivery technology is based on the proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20; Halozyme Therapeutics, Inc.) that facilitates the subcutaneous (SC) delivery of co-administered therapeutics. rHuPH20 works by degrad
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1492d466ca5574e9717f164291ec6c73
https://doaj.org/article/db94eb4355944ba4a608ab317f5696f8
https://doaj.org/article/db94eb4355944ba4a608ab317f5696f8
Autor:
Daniel C. Maneval, David W. Kang, Marie A. Printz, Samuel S. Dychter, Barry J. Sugarman, Rena Harrigan, Monica L. Zepeda, Jennifer Souratha, Emanuel P. DeNoia
Publikováno v:
Current Therapeutic Research, Clinical and Experimental
Current Therapeutic Research, Vol 93, Iss, Pp 100604-(2020)
Current Therapeutic Research, Vol 93, Iss, Pp 100604-(2020)
Background Recombinant human hyaluronidase PH20 (rHuPH20) is used in subcutaneous formulations (eg, RITUXAN HYCELA [rituximab and hyaluronidase human], HERCEPTIN HYLECTA [trastuzumab and hyaluronidase-oysk], PHESGO [pertuzumab/trastuzumab/hyaluronida
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f288b82b197ef8fb713739350bf1fa9
http://europepmc.org/articles/PMC7490523
http://europepmc.org/articles/PMC7490523
Autor:
Sybille Sauter, Michael J. LaBarre, Rose E. Sekulovich, Kenneth W. Locke, Mann Muhsin, Curtis B. Thompson, Celine Derunes, Chris L. Caster, Daniel C. Maneval
Hyaluronan (or hyaluronic acid, HA) is a nonsulfated, negatively charged, single-chain megadalton glycosaminoglycan distributed through the body, especially in soft connective tissue. In many solid tumors, HA accumulates in the extracellular matrix,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4bfa188e3a0a4a220ef105d5d945dddf
https://doi.org/10.1016/b978-0-444-64081-9.00009-7
https://doi.org/10.1016/b978-0-444-64081-9.00009-7
Publikováno v:
Drug Delivery
ENHANZE® drug delivery technology is based on the proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20; Halozyme Therapeutics, Inc.) that facilitates the subcutaneous (SC) delivery of co‐administered therapeutics. rHuPH20 works by degr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::21154e8dcee916b82ca6ab1a91ddf1f2
https://pubmed.ncbi.nlm.nih.gov/30744432
https://pubmed.ncbi.nlm.nih.gov/30744432